ABIVAX SUCCESSFULLY COMPLETES FIRST-IN-MAN STUDY OF ABX464, A HIGHLY DIFFERENTIATED SMALL MOLECULE TARGETING HIV

ABIVAX today announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.

AXB464 is a novel, small molecule with the potential to inhibit HIV replication. Through its unique mode of action, ABX464 is the first anti-HIV drug able to induce a long-lasting HIV viral load reduction even after treatment has been stopped, in pre-clinical testing in mice.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41